[Histological changes observed in the treatment of endometrial glandular epithelioma with lynestrenol].
Lynestrenol, which is a progestogen with weak oestrogenic features, has numerous theorretical advantages in the hormonal treatment of endometrial carcinoma of the body of the uterus when associated with combined radiotherapy and surgery. Iinitial clinical impressions were confirmed by a study of the histological modifications brought about by lynestrenol in this kind of tumour in which are included some poorly differentiated or undifferentiated cases.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D004717:Endometrium / Q000473:pathology; D004967:Estrogens / Q000502:physiology; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014599:Uterus / Q000473:pathology*
D004967:Estrogens; D008234:Lynestrenol
Etude des modifications histologiques observées lors du traitement de l'épithélioma glandulaire endométrial par le lynestrénol.